Antitumor effects of carnertinib in castration resistant prostate cancer models: A comparative study with erlotinib

Prostate

Volumn 71, Issue 14, 2011, Pages 1481-1491

  Gravina, Giovanni Luca ^a,b   Marampon, Francesco ^a,b   Piccolella, Margherita ^c   Biordi, Leda ^a   Ficorella, Corrado ^a   Motta, Marcella ^c   Jannini, Emmanuele A ^a   Tombolini, Vincenzo ^a   Festuccia, Claudio ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

bicalutamide; castrated resistant prostate cancer; epidermal growth factor receptors; erlotinib and carnertinib

Indexed keywords

ACTIN; CANERTINIB; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; ANILIDE; ANTIANDROGEN; BICALUTAMIDE; MORPHOLINE DERIVATIVE; NITRILE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TOLUENESULFONIC ACID DERIVATIVE;

ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CELL DIVISION; CELL LINE; COMPARATIVE STUDY; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; EPITHELIUM CELL; HUMAN; ORCHIECTOMY; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; APOPTOSIS; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; HUMANS; MALE; MICE, NUDE; MORPHOLINES; NITRILES; ORCHIECTOMY; PROSTATE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TOSYL COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052084104     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21363     Document Type: Article

References (30)

1. Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Earp HS III., Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 2005; 11: 1704-1712. (Pubitemid 40471831)
2. El Sheikh SS, Domin J, Abel P, et al. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 2004; 6: 846-853. (Pubitemid 40041504)
3. Blackledge G,. Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy. J Urol 2003; 170: S77-S83. (Pubitemid 37413947)
4. Perez CA, Chen H, Shyr Y, Courtney R, Zheng W, Cai Q, Hwang M, Jaboin J, Schleicher S, Moretti L, Wills M, Smith JA, Lu B,. The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer. J Urol 2010; 183: 2062-2069.
5. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F,. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 2002; 8: 3438-3444. (Pubitemid 35340719)
6. Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92: 1918-1925. (Pubitemid 32036922)
7. Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Vessella RL, Vicentini C, Bologna M,. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Endocr Relat Cancer 2007; 14: 601-611. (Pubitemid 350074050)
8. Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M,. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol 2003; 129: 165-174. (Pubitemid 36583697)
9. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G,. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063. (Pubitemid 30305105)
10. Canil CM, Moore MJ, Winquist E, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005; 23: 455-460. (Pubitemid 46224221)
11. Small EJ, Fontana J, Tannir N, Dipaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF,. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 2007; 100: 765-769. (Pubitemid 47360196)
12. Curigliano G, De Braud F, Teresa Sandri M, Renne G, Zorzino L, Scardino E, Rocco B, Spitaleri G, De Pas T, Noberasco C, Nole F, Verweij F, Matei V, De Cobelli O,. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: Quality of life and surrogate markers of activity. Anticancer Drugs 2007; 18: 949-954. (Pubitemid 47220714)
13. Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB,. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007; 7: 142-147.
14. Festuccia C, Gravina GL, Biordi L, D'Ascenzo S, Dolo V, Ficorella C, Ricevuto E, Tombolini V,. Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Prostate 2009; 69: 1529-1537.
15. Sinisi AA, Chieffi P, Pasquali D, Kisslinger A, Staibano S, Bellastella A, Tramontano D,. EPN: A novel epithelial cell line derived from human prostate tissue. In Vitro Cell Dev Biol Anim 2002; 23: 165-172. (Pubitemid 34507488)
16. Tepper CG, Boucher DL, Ryan PE, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002; 62: 6606-6614. (Pubitemid 35364127)
17. Craft N, Shostak Y, Carey M, et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5: 280-285. (Pubitemid 29124362)
18. Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK,. Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 2002; 23: 967-975. (Pubitemid 34752952)
19. Kokontis JM, Hay N, Liao S,. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998; 12: 941-953. (Pubitemid 30660662)
20. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET,. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001; 47: 212-221. (Pubitemid 32378373)
21. Zhao H, Dupont J, Yakar S, et al. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 2004; 23: 786-794. (Pubitemid 38241279)
22. Bonaccorsi L, Carloni V, Muratori M, et al. Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology 2000; 141: 3172-3182. (Pubitemid 32269005)
23. Scaccianoce E, Festuccia C, Dondi D, et al. Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor. Oncol Res 2003; 14: 101-112. (Pubitemid 38166339)
24. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL,. The current state of preclinical prostate cancer animal models. Prostate 2008; 68: 629-639. (Pubitemid 351614641)
25. Fu M, Wang C, Zhang X, Pestell RG,. Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol 2004; 68: 1199-1208. (Pubitemid 39094285)
26. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22: 2812-2822. (Pubitemid 36609595)
27. Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M,. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr Relat Cancer 2005; 12: 983-998. (Pubitemid 41815791)
28. Wallasch C, Weiss FU, Niederfellner G, et al. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 1995; 14: 4267-4275.
29. Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004; 11: 793-814. (Pubitemid 40065552)
30. Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, Ficorella C, Ricevuto E, Bologna M,. Her2 crosstalks with TrkA in a subset of prostate cancer cells: Rationale for a guided dual treatment. Prostate 2009; 69: 337-345.